Recommendations for the use of sapropterin in phenylketonuria

Molecular Genetics and Metabolism

Volumn 106, Issue 3, 2012, Pages 269-276

  Cunningham, Amy ^a   Bausell, Heather ^b   Brown, Mary ^c   Chapman, Maggie ^d   DeFouw, Kari ^e   Ernst, Sharon ^f   McClure, Julie ^g   McCune, Helen ^h   O'Steen, Donna ⁱ   Pender, Amy ^j   Skrabal, Jill ^k   Wessel, Ann ^l   Jurecki, Elaina ^m   Shediac, Renée ^m   Prasad, Suyash ^m   Gillis, Jane ^d,n   Cederbaum, Stephen ^o  

^a TULANE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b CHILDREN'S MEMORIAL HOSPITAL   (United States)

^c INTERMOUNTAIN HEALTHCARE   (United States)

^d IWK HEALTH CENTRE   (Canada)

^e Children's Hospital of Wisconsin ^*  (United States)

^f UNIVERSITY OF UTAH   (United States)

^g UNIVERSITY OF NORTH CAROLINA   (United States)

^h UNIVERSITY OF FLORIDA   (United States)

ⁱ UNIVERSITY OF SOUTH FLORIDA   (United States)

^j MCMASTER CHILDREN S HOSPITAL   (Canada)

^k UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^l BOSTON CHILDREN S HOSPITAL   (United States)

^m BIOMARIN PHARMACEUTICAL INC   (United States)

ⁿ DALHOUSIE UNIVERSITY   (Canada)

^o UNIVERSITY OF CALIFORNIA   (United States)

more..

Author keywords

Phenylketonuria; Sapropterin; Tetrahydrobiopterin

Indexed keywords

LEVODOPA; METHOTREXATE; PHENYLALANINE; PHOSPHODIESTERASE V INHIBITOR; PSYCHOTROPIC AGENT; SAPROPTERIN; WATER;

AMINO ACID BLOOD LEVEL; ANXIETY; ARTICLE; BLOOD CELL COUNT; BLOOD CHEMISTRY; BODY MASS; BODY WEIGHT; CASE REPORT; CLINICAL PROTOCOL; COGNITION; COGNITIVE DEFECT; DIET MODIFICATION; DIET THERAPY; DIETARY INTAKE; DIETARY PHENYLALANINE TOLERANCE; DIETITIAN; DISEASE SEVERITY; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG RESPONSE; DRUG SAFETY; EVIDENCE BASED MEDICINE; FAMILY; FOOD; GASTROINTESTINAL SYMPTOM; HUMAN; HYPERPHENYLALANINEMIA; INFANT; INFORMED CONSENT; IRRITABILITY; LIFESTYLE MODIFICATION; LONG TERM CARE; MEDICAL FOOD; MEDICAL HISTORY; MENTAL DEFICIENCY; MENTAL HEALTH CARE; METABOLIC REGULATION; MILD HYPERPHENYLALANINEMIA; NORTH AMERICA; NUTRITIONAL STATUS; PATIENT ASSESSMENT; PATIENT COMPLIANCE; PATIENT COUNSELING; PATIENT EDUCATION; PATIENT MONITORING; PATIENT SELECTION; PHENYLKETONURIA; PHYSICAL EXAMINATION; PHYSICIAN; PREGNANCY; PREGNANT WOMAN; PRESCHOOL CHILD; PRIORITY JOURNAL; PROTEIN INTAKE; PSYCHOSOCIAL DISORDER; RISK FACTOR; SCREENING TEST; SIDE EFFECT; TABLET FORMULATION; TREATMENT INDICATION; TREATMENT OUTCOME; TREATMENT REFUSAL;

BIOPTERIN; CHILD, PRESCHOOL; DIET; HUMANS; MONITORING, PHYSIOLOGIC; NORTH AMERICA; PHENYLALANINE; PHENYLKETONURIAS;

EID: 84862535401     PISSN: 10967192     EISSN: 10967206     Source Type: Journal    
DOI: 10.1016/j.ymgme.2012.04.004     Document Type: Article

References (62)

1. Scriver C.R., Kaufman S. Hyperphenylalaninemia: phenylalanine hydroxylase deficiency. The Metabolic and Molecular Bases of Inherited Disease 2001, 1667-1724. McGraw-Hill, New York. C.R. Scriver, A.L. Beaudet, W.S. Sly, D. Valle, B. Childs, B. Vogelstein (Eds.).
2. Phenylalanine Hydroxylase Locus Knowledgebase (PAHdb) http://www.pahdb.mcgill.ca/.
3. Walter J.H., White F.J., Hall S.K., MacDonald A., Rylance G., Boneh A., Francis D.E., Shortland G.J., Schmidt M., Vail A. How practical are recommendations for dietary control in phenylketonuria?. Lancet 2002, 360:55-57.
4. Enns G.M., Koch R., Brumm V., Blakely E., Suter R., Jurecki E. Suboptimal outcomes in patients with PKU treated early with diet alone: revisiting the evidence. Mol. Genet. Metab. 2010, 101:99-109.
5. Muntau A.C., Roschinger W., Habich M., Demmelmair H., Hoffmann B., Sommerhoff C.P., Roscher A.A. Tetrahydrobiopterin as an alternative treatment for mild phenylketonuria. N. Engl. J. Med. 2002, 347:2122-2132.
6. Mitchell J.J., Wilcken B., Alexander I., Ellaway C., O'Grady H., Wiley V., Earl J., Christodoulou J. Tetrahydrobiopterin-responsive phenylketonuria: the New South Wales experience. Mol. Genet. Metab. 2005, 86(Suppl. 1):S81-S85.
7. Bernegger C., Blau N. High frequency of tetrahydrobiopterin-responsiveness among hyperphenylalaninemias: a study of 1,919 patients observed from 1988 to 2002. Mol. Genet. Metab. 2002, 77:304-313.
8. Burton B.K., Grange D.K., Milanowski A., Vockley G., Feillet F., Crombez E.A., Abadie V., Harding C.O., Cederbaum S., Dobbelaere D., Smith A., Dorenbaum A. The response of patients with phenylketonuria and elevated serum phenylalanine to treatment with oral sapropterin dihydrochloride (6R-tetrahydrobiopterin): a phase II, multicentre, open-label, screening study. J. Inherit. Metab. Dis. 2007, 30:700-707.
9. Levy H.L., Milanowski A., Chakrapani A., Cleary M., Lee P., Trefz F.K., Whitley C.B., Feillet F., Feigenbaum A.S., Bebchuk J.D., Christ-Schmidt H., Dorenbaum A. Efficacy of sapropterin dihydrochloride (tetrahydrobiopterin, 6R-BH4) for reduction of phenylalanine concentration in patients with phenylketonuria: a phase III randomised placebo-controlled study. Lancet 2007, 370:504-510.
10. Trefz F.K., Burton B.K., Longo N., Casanova M.M., Gruskin D.J., Dorenbaum A., Kakkis E.D., Crombez E.A., Grange D.K., Harmatz P., Lipson M.H., Milanowski A., Randolph L.M., Vockley J., Whitley C.B., Wolff J.A., Bebchuk J., Christ-Schmidt H., Hennermann J.B. Efficacy of sapropterin dihydrochloride in increasing phenylalanine tolerance in children with phenylketonuria: a phase III, randomized, double-blind, placebo-controlled study. J. Pediatr. 2009, 154:700-707.
11. Levy H., Burton B., Cederbaum S., Scriver C. Recommendations for evaluation of responsiveness to tetrahydrobiopterin (BH(4)) in phenylketonuria and its use in treatment. Mol. Genet. Metab. 2007, 92:287-291.
12. 4) in phenylketonuria. Top. Clin. Nutr. 2008, 23:149-157.
13. Blau N., Belanger-Quintana A., Demirkol M., Feillet F., Giovannini M., MacDonald A., Trefz F.K., van Spronsen F.J. Optimizing the use of sapropterin (BH(4)) in the management of phenylketonuria. Mol. Genet. Metab. 2009, 96:158-163.
14. Hanley W.B. Non-PKU mild hyperphenylalaninemia (MHP)-the dilemma. Mol. Genet. Metab. 2011, 104:23-26.
15. van Spronsen F.J. Mild hyperphenylalaninemia: to treat or not to treat. J. Inherit. Metab. Dis. 2011, 34:651-656.
16. Campistol J., Gassio R., Artuch R., Vilaseca M.A. Neurocognitive function in mild hyperphenylalaninemia. Dev. Med. Child Neurol. 2011, 53:405-408.
17. Cederbaum S. Tetrahydrobiopterin and PKU: into the future. J. Pediatr. 2011, 158:351-353.
18. Huijbregts S.C., de Sonneville L.M., Licht R., van Spronsen F.J., Verkerk P.H., Sergeant J.A. Sustained attention and inhibition of cognitive interference in treated phenylketonuria: associations with concurrent and lifetime phenylalanine concentrations. Neuropsychologia 2002, 40:7-15.
19. Huijbregts S., de Sonneville L., Licht R., Sergeant J., van Spronsen F. Inhibition of prepotent responding and attentional flexibility in treated phenylketonuria. Dev. Neuropsychol. 2002, 22:481-499.
20. Burgard P., Rey F., Rupp A., Abadie V., Rey J. Neuropsychologic functions of early treated patients with phenylketonuria, on and off diet: results of a cross-national and cross-sectional study. Pediatr. Res. 1997, 41:368-374.
21. Viau K.S., Wengreen H.J., Ernst S.L., Cantor N.L., Furtado L.V., Longo N. Correlation of age-specific phenylalanine levels with intellectual outcome in patients with phenylketonuria. J. Inherit. Metab. Dis. 2011, 34:963-971.
22. Dawson C., Murphy E., Maritz C., Chan H., Ellerton C., Carpenter R.H., Lachmann R.H. Dietary treatment of phenylketonuria: the effect of phenylalanine on reaction time. J. Inherit. Metab. Dis. 2011, 34:449-454.
23. Albrecht J., Garbade S.F., Burgard P. Neuropsychological speed tests and blood phenylalanine levels in patients with phenylketonuria: a meta-analysis. Neurosci. Biobehav. Rev. 2009, 33:414-421.
24. Burton B.K., Adams D.J., Grange D.K., Malone J.I., Jurecki E., Bausell H., Marra K.D., Sprietsma L., Swan K.T. Tetrahydrobiopterin therapy for phenylketonuria in infants and young children. J. Pediatr. 2011, 158:410-415.
25. Blau N., Belanger-Quintana A., Demirkol M., Feillet F., Giovannini M., MacDonald A., Trefz F.K., van Spronsen F. Management of phenylketonuria in Europe: survey results from 19 countries. Mol. Genet. Metab. 2010, 99:109-115.
26. Effect of Kuvan on Neurocognitive Function, Safety, and Pharmacokinetics in Children with PKU Accessed on 1 March, 2012. http://clinicaltrials.gov/ct2/show/NCT00838435?term=kuvan&rank=9.
27. Longo N., Burton B., Dimmock D., Feigenbaum A., Potter M., Stockler S., Siriwardena K., Lang W., Kim S., Jurecki E., Prasad S. Safety and efficacy of sapropterin in children aged 0 to 6years with phenylketonuria. Preliminary Findings from a Long Term Open Label Study, 2012 American College of Medical Genetics Annual Clinical Genetics Meeting, Charlotte, North Carolina 2012.
28. Koch R. Maternal phenylketonuria and tetrahydrobiopterin. Pediatrics 2008, 122:1367-1368.
29. Moseley K., Skrabal J., Yano S., Koch R. Sapropterin dihydrochloride (6R-BH4) and maternal phenylketonuria two case studies. Infant Child Adolesc. Nutr. 2009, 1:262-266.
30. Koch R., Moseley K.D. Maternal phenylketonuria and tetrahydrobiopterin. Mol. Genet. Metab. 2009, 98:37.
31. Cunningham A., Pridjian G., Smith J., Andersson H.C. PKU treatment with tetrahydrobiopterin (sapropterin) during pregnancy. Mol. Genet. Metab. 2009, 98:24.
32. KUVAN® US Prescribing Information 2007, BioMarin Pharmaceutical Inc., Novato, CA, Available at www.kuvan.com.
33. Koch R., Hanley W., Levy H., Matalon K., Matalon R., Rouse B., Trefz F., Güttler F., Azen C., Platt L., Waisbren S., Widaman K., Ning J., Friedman E.G., de la Cruz F. The maternal phenylketonuria international study: 1984-2002. Pediatrics 2003, 112:1523-1529.
34. Platt L.D., Koch R., Hanley W.B., Levy H.L., Matalon R., Rouse B., Trefz F., de la Cruz F., Guttler F., Azen C., Friedman E.G. The international study of pregnancy outcome in women with maternal phenylketonuria: report of a 12-year study. Am. J. Obstet. Gynecol. 2000, 182:326-333.
35. Brown A.S., Fernhoff P.M., Waisbren S.E., Frazier D.M., Singh R., Rohr F., Morris J.M., Kenneson A., MacDonald P., Gwinn M., Honein M., Rasmussen S.A. Barriers to successful dietary control among pregnant women with phenylketonuria. Genet. Med. 2002, 4:84-89.
36. Rohr F., Munier A., Sullivan D., Bailey I., Gennaccaro M., Levy H., Brereton H., Gleason S., Goss B., Lesperance E., Moseley K., Singh R., Tonyes L., Vespa H., Waisbren S. The resource mothers study of maternal phenylketonuria: preliminary findings. J. Inherit. Metab. Dis. 2004, 27:145-155.
37. Lee P.J., Amos A., Robertson L., Fitzgerald B., Hoskin R., Lilburn M., Weetch E., Murphy G. Adults with late diagnosed PKU and severe challenging behaviour: a randomised placebo-controlled trial of a phenylalanine-restricted diet. J. Neurol. Neurosurg. Psychiatry 2009, 80:631-635.
38. Vernon H.J., Koerner C.B., Johnson M.R., Bergner A., Hamosh A. Introduction of sapropterin dihydrochloride as standard of care in patients with phenylketonuria. Mol. Genet. Metab. 2010, 100:229-233.
39. Moseley K.D., Azen C., Ottina M.J., Koch R., Yano S. Pilot study to evaluate the effects of Kuvan on adult individuals with phenylketonuria with measurable maladaptive behaviors. J. Inherit. Metab. Dis. 2010, 33:S116.
40. Aman M.G., Singh N.N., Stewart A.W., Field C.J. The aberrant behavior checklist: a behavior rating scale for the assessment of treatment effects. Am. J. Ment. Defic. 1985, 89:485-491.
41. Cade J.E., Burley V.J., Warm D.L., Thompson R.L., Margetts B.M. Food-frequency questionnaires: a review of their design, validation and utilisation. Nutr. Res. Rev. 2004, 17:5-22.
42. Burton B.K., Nowacka M., Hennermann J.B., Lipson M., Grange D.K., Chakrapani A., Trefz F., Dorenbaum A., Imperiale M., Kim S.S., Fernhoff P.M. Safety of extended treatment with sapropterin dihydrochloride in patients with phenylketonuria: results of a phase 3b study. Mol. Genet. Metab. 2011, 103:315-322.
43. Gioia G.A., Isquith P.K., Guy S., Kenworthy L. Behavior Rating Inventory of Executive Function (BRIEF) 2000, Psychological Assessment Resources, Lutz, Florida.
44. Jellinek M.S., Murphy J.M., Little M., Pagano M.E., Comer D.M., Kelleher K.J. Use of the Pediatric Symptom Checklist to screen for psychosocial problems in pediatric primary care: a national feasibility study. Arch. Pediatr. Adolesc. Med. 1999, 153:254-260.
45. Wieland J., Wardenaar K.J., Fontein E., Zitman F.G. Utility of the Brief Symptom Inventory (BSI) in psychiatric outpatients with intellectual disabilities. J. Intellect. Disabil. Res. 2011, 1-11.
46. Waisbren S., White D.A. Screening for cognitive and social-emotional problems in individuals with PKU: tools for use in the metabolic clinic. Mol. Genet. Metab. 2010, 99:S96-S99.
47. Leviton L., Vespa H., Burton B.K. Mental health screening in the phenylketonuria (PKU) clinic. 2011 American College of Medical Genetics Annual Clinical Genetics Meeting, Vancouver, British Columbia, Canada 2011.
48. Erstad B.L. Which weight for weight-based dosage regimens in obese patients?. Am. J. Health Syst. Pharm. 2002, 59:2105-2110.
49. van Rijn M., Hoeksma M., Sauer P.J., Modderman P., Reijngoud D.J., van Spronsen F.J. Adult patients with well-controlled phenylketonuria tolerate incidental additional intake of phenylalanine. Ann. Nutr. Metab. 2011, 58:94-100.
50. U.S. Department of Agriculture (USDA) National Nutrient Database for Standard Reference Search Page Accessed on 1 March, 2012. http://www.nal.usda.gov/fnic/foodcomp/search/.
51. Pennington J.A.T., Spungen J. Bowes and Church's Food Values of Portions Commonly Used 2009, Lippincott Williams & Wilkins, Philadelphia.
52. Gordon P., Thomas J.A., Suter R., Jurecki E. Evolving patient selection and clinical benefit criteria for sapropterin dihydrochloride (Kuvan®) treatment of PKU patients. Mol. Genet. Metab. 2012, 105:672-676.
53. Singh R.H., Quirk M.E. Using change in plasma phenylalanine concentrations and ability to liberalize diet to classify responsiveness to tetrahydrobiopterin therapy in patients with phenylketonuria. Mol. Genet. Metab. 2011, 104:485-491.
54. White D.A., Grange D.K., Christ S.E. Neurocognitive findings in individuals with phenylketonuria and treatment with sapropterin dihydrochloride (BH4). J. Inherit. Metab. Dis. 2010, 33:S112.
55. Christ S.E., Peck D., Moffitt A., Hillman R. Brain function in individuals with PKU treated with Kuvan: evidence from functional magnetic resonance imaging. J. Inherit. Metab. Dis. 2010, 33:S111.
56. Safety and Therapeutic Effects of Sapropterin Dihydrochloride on Neuropsychiatric Symptoms in Phenylketonuria (PKU) Patients Accessed on 1 March, 2012. http://clinicaltrials.gov/ct2/show/NCT01114737?term=kuvan&rank=13.
57. Prasad S., Burton B., Feigenbaum A., Grant M., Hendren R., Mardach R., Phillips J., Sanchez-Valle A., Singh R., Siriwardena K., Thomas J., Stahl S., Lang W., Kim S., Jurecki E. Baseline findings in the first 60 subjects in PKU-016: a double-blind, placebo-controlled, randomized study to evaluate the safety and therapeutic effects of sapropterin dihydrochloride on neuropsychiatric symptoms in subjects with phenylketonuria (PKU). 2012 American College of Medical Genetics Annual Clinical Genetics Meeting, Charlotte, North Carolina 2012.
58. White F.J., Gallagher J., Walter J.H. Variability in blood phenylalanine in patients with PKU. J. Inherit. Metab. Dis. 2011, 34:S94.
59. Anastasoaie V., Kurzius L., Forbes P., Waisbren S. Stability of blood phenylalanine levels and IQ in children with phenylketonuria. Mol. Genet. Metab. 2008, 95:17-20.
60. Burton B.K., Bausell H., Katz R., Laduca H., Sullivan C. Sapropterin therapy increases stability of blood phenylalanine levels in patients with BH4-responsive phenylketonuria (PKU). Mol. Genet. Metab. 2010, 101:110-114.
61. Humphrey M., Nation J., Francis I., Boneh A. Effect of tetrahydrobiopterin on Phe/Tyr ratios and variation in Phe levels in tetrahydrobiopterin responsive PKU patients. Mol. Genet. Metab. 2011, 104:89-92.
62. MacLeod E.L., Gleason S.T., van Calcar S.C., Ney D.M. Reassessment of phenylalanine tolerance in adults with phenylketonuria is needed as body mass changes. Mol. Genet. Metab. 2009, 98:331-337.